French Biotech firm Enterome, partly owned by the Lundbeck Foundation, has entered a strategic research and development partnership regarding food allergies and inflammatory bowel disease (IBD) with Nestlé Health Science, according to a company press release.
Enterome describes two specific goals of the collaboration, the first of which concerns the successful development and commercialization of Enterome’s pipeline candidate slated for clinical testing next year, EB1010, a potential treatment for IBD and food allergies.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Demant rejects criticisms of lobbying efforts against OTC channel: "That’s how America works"
To ensure users receive a high-quality device, CEO Søren Nielsen says Demant has lobbied the FDA through a US-based industry association as it attempts to established the rules for the upcoming over-the-counter hearing aids sales channel.
Sonova downgrades, blames high costs and weak results from key markets
The hearing aid giant now expects revenue growth of 15-19% measured in local currencies, compared to a previous 17-21%.
Demant CEO highlights strong performance from Diagnostics, acknowledges Communications letdown
The Danish hearing aid manufacturer’s diagnostics business area is a beacon of light among gloomy H1 financial figures, mostly coming from headset firm Epos, says CEO Søren Nielsen.
Analyst to hone in on Vyepti rollout and patient uptake in imminent Lundbeck report
The preventive migraine treatment, Vyepti, will likely be a key element of the Danish pharmaceutical firm’s upcoming second quarterly report on Wednesday.
US downswing reflects shift in underlying demand, says Demant CEO
Demand for hearing aids on the US market will return in the future, according to Demant CEO Søren Nielsen, who thinks people are postponing the decision to acquire a device due to the challenging economic environment.
Senior Toxicologist 
Quality coordinator for Aseptic Production, ALK 
Head of Regulatory Services Denmark 
Principal Laboratory Technologist Medicinal Chemistry 
Global Quality Director (Business Unit Quality Lead) 
Lead Auditor – Senior Quality Assurance Specialist 
Clinical Project/Trial Manager, Synklino 
Clinical Biometrics Oversight Lead 
Scientist Radiochemistry 
Clinical Trial Manager - Black Swans Exist 
Senior Clinical Trial Manager - Black Swans Exist 
Director Regulatory Affairs